Walgreens and Verily announce partnerships for diabetes, medication adherence

Walgreens store
“This relationship affords us the opportunity to jointly tackle real-world issues that significantly impact the health of individuals and communities,” said Verily CEO Andrew Conrad.

Walgreens Boots Alliance and Verily, Alphabet Inc.’s life sciences research arm, announced multiple plans on Wednesday to help patients with chronic conditions.

One project uses “devices and other approaches” to improve medication adherence, and the other “provides tools, coaching and remote access to specialty doctors to help people with diabetes to manage their condition anytime, anywhere,” according to a press release.

The diabetes solution, Onduo, will target Walgreens employees and family members through the company’s employee health plan.  

Conference

2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

On Thursday, the company reported a nearly 10% increase in sales in the first quarter of fiscal year 2019, which ended on Nov. 30, as well as a 45.7% jump in earnings per share.

This performance will allow the company to grow and transform its business, including through new partnerships, said Stefano Pessina, executive vice chairman and CEO of Walgreens Boots Alliance, highlighting the new initiative with Verily as well as its existing collaborations with Kroger, FedEx, and Humana.

RELATED: Walgreens partnership would give Humana more leverage in shifting market

In addition, Walgreens plans to bring lab testing services to at least 600 of its stores over the next four years by teaming up with LabCorp.

Verily CEO Andrew Conrad said his company, like Walgreens, sees the need to develop better solutions for patients with chronic conditions.

“This relationship affords us the opportunity to jointly tackle real-world issues that significantly impact the health of individuals and communities,” he said, noting that medication adherence is “one of the most significant and costly barriers to improving patient outcomes.”

The companies seek to help patients through long-term, lasting solutions, and they aim to work within the context of integrated and value-based care, Pessina said.

Partnerships like these could be Walgreens’ way of keeping up with fellow pharmacy companies CVS and Express Scripts amid their mergers with Aetna and Cigna, respectively. Cigna closed its $67 billion acquisition of Express Scripts on Thursday, and the CVS-Aetna deal is inching forward in federal court.

Walgreens has also reportedly been in discussions with Humana for the companies to take equity stakes in one another, a move that would give the insurer more leverage in a shifting market.

Suggested Articles

Health insurers’ financial performance is on a continuing upward trend, but political and legal risks could pose a threat to that growth.

Senate lawmakers released a draft package of legislation aimed at curbing healthcare costs they said they believe they can pass on a bipartisan basis.

Attorneys general seeking to defend the ACA argue that their opponents—including the DOJ—have poor legal standing to challenge the law.